Blockade of PD-1-PD-L1 axis interaction, therefore, offers a promising strategy to reinvigorate exhausted CD8+ T cells and this has been confirmed in clinical trials demonstrating durable objective responses in advanced HCC patients treated with nivolumab or pembrolizumab [135,136,137]. Here, PDCD1 is linked to hepatocellular carcinoma.